Concepedia

Gabriel Tremblay

GT

20

Publications

342

Citations

12

H-Index

1962

Active since

Affiliations

Novartis (United States)(Current)

Cytel (United States)

University of Glasgow

Eisai (United States)

Otto-von-Guericke University Magdeburg

Gabriel Tremblay is an author at Novartis (United States) specializing in medicine, hematology, and oncology.

ORCID

Top concepts

Publications per year

1962–2023

20

Publications

20

Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials

Jay Park, Behnam Sharif, Ofir Harari et al. · JAMA Network Open · 2022 · 44 citations · Full text

Systematic review of health state utility values for acute myeloid leukemia

Anna Forsythe, Patricia Brandt, Mike Dolph et al. · ClinicoEconomics and Outcomes Research · 2018 · 31 citations · Full text

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Gabriel Tremblay, David Chandiwana, Mike Dolph et al. · Cancer Management and Research · 2018 · 25 citations · Full text

Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data

Gabriel Tremblay, M Groff, Laura Iadeluca et al. · Future Oncology · 2022 · 21 citations · Full text

A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data

Gabriel Tremblay, Patrick A. Haines, Andrew Briggs · Journal of health economics and outcomes research · 2015 · 21 citations · Full text

Rows per page

1–5 of 20